AbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors
Another Week, Another Index Record | Lkive Stock
ABBV's Acquisition Spree Continues: Buy, Sell or Hold the Stock?
ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline
AbbVie (ABBV.US) has reached an acquisition agreement to expand its presence in the field of autoimmune diseases.
AbbVie (ABBV.US) announced that it has reached a final agreement with Nimble Therapeutics.
EMA Panel Endorses Lilly's Omvoh for Expanded Use in Crohn's Disease
AbbVie Announces Leadership Change With New Appointment
Weekly Buzz: Tech stocks hit high scores on ominous day
AbbVie: David R. Purdue Will Be Senior Vice President, Controller
AbbVie: Kevin K. Buckbee, Senior Vice President, Controller, Plans to Retire From Controller Role Effective March 1
This Drugmaker's (ABBV) Parkinson's Medication Just Cleared A Key Hurdle – Is It Primed For A Monster Year In 2025?
Market Mixed on Friday the 13th | Livestock
AbbVie to Buy Nimble Therapeutics
AbbVie: Nimble Shareholders Eligible for Potential Development Milestone Payment >ABBV
Express News | Abbvie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline
AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline
Thursday Ends in Index Declines | Wall Street Today
Market Falls Thursday, Producer Inflation Grows, and Tech Pulls Back From Records | LiveStock
Unlearn's 2024 Achievements Drive Innovation in AI for Clinical Development
Express News | Hungary's Richter CEO Says Previous Pace of Growth in Dividend Payouts Cannot Be Maintained